VRDN Q1 2024 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$3B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$72,000-26.5% YoY

Gross Profit

$72,000100.0% margin

Operating Income

-$56M-77634.7% margin

Net Income

-$49M-67419.4% margin

EPS (Diluted)

$-0.79

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$45M

Free Cash Flow

-$45M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$630M

Total Liabilities

$48M

Stockholders' Equity

$583M

Cash & Equivalents

$92M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$72,000	$98,000	-26.5%
Gross Profit	$72,000	$98,000	-26.5%
Operating Income	-$56M	-$72M	+22.9%
Net Income	-$49M	-$68M	+28.8%

Revenue Segments

Collaboration Revenue

$100,000100%